Hero background

Discover how we can accelerate research that redefines the landscape of type 1 diabetes.

Application window is 
09:00 CET on 4 January to 
15:00 CET on 11 February 2027

A type 1 diabetes research funding program from Sanofi

Thumbnail - Manifesto

Type 1 diabetes (T1D) is a progressive autoimmune disorder characterized by the destruction of insulin-producing beta cells in the pancreas.1,2 The disease process begins months to years before clinical symptoms appear3 and can be detected in presymptomatic individuals.4 Detection of early-stage disease and the development of effective management strategies are important to improving outcomes and quality of life of those affected.3,5  
Sanofi launched the T1D Innovation Grant Program to support research in T1D to drive early detection and innovation that may lead to an improved T1D trajectory in individuals across the different stages of T1D. 

Why should you apply for the T1D Innovation Grant Program?

The T1D Innovation Grant Program empowers researchers with the funding needed to accelerate breakthroughs in T1D. Here’s why you should consider applying:

Tile 1

Streamlined Application Process:

Researchers can submit their grant application on a dedicated platform

Tile 2

Review by Impartial Experts:

An independent, external panel of seven international T1D experts will evaluate all submissions

Tile 3

Substantial Funding Opportunity:

Successful applicants can receive a grant of up to €140,000 for each research project, with a total of €700,000 available across all successful grant applications

Tile 4

Global Reach and Impact:

A truly global initiative, the T1D Innovation Grant Program is open to applicants from 37 countries across key regions

The T1D Innovation Grant Program will be open to submissions soon – sign up now to stay informed!

Sign Up
  1. Phillip M, et al. Diabetologia. 2024;67(9):1731-59 [simultaneously published in Diabetes Care. 2024;47(8):1276-98].
  2. Herold KC, et al. Nat Rev Immunol. 2024;24:435-451.
  3. Besser REJ, et al. Arch Dis Child. 2022;107(9):790-5.
  4. American Diabetes Association Professional Practice Committee. Diabetes Care. 2026;49(Suppl.1):S27–S49.
  5. Greenbaum CJ. Diabetes. 2021;70:1029-37.